New funding to support novel DNA vaccine for therapy of leishmaniasis
Funding has been awarded by the GHIT Fund to EVI and its partners from Nagasaki University, German biopharmaceutical firm Mologen AG, Charité - Universitätsmedizin Berlin and the London School of Hygiene and Tropical Medicine (LSHTM) to support the completion of the preclinical development of a novel leishmaniasis vaccine candidate and for preparing the conduct of a future Phase I clinical trial.
Leishmaniasis is a disease caused by parasites spread by sand flies. It is common in parts of Asia, the Middle East, Africa, and Latin America, where it can cause a variety of problems for those infected. The cutaneous form of the disease can lead to moderate or disfiguring skin sores, while visceral leishmaniasis, which attacks internal organs, is frequently fatal. No vaccine is currently licensed for any form of human leishmaniasis, and available drug treatment options are limited. Moreover, drugs are increasingly compromised by drug resistance. The GHIT Fund is supporting work on a candidate vaccine that takes aim at leishmaniasis with an innovative design that aligns with the complex immune mechanisms that must be triggered to effectively treat or prevent the disease.